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+e spectrum of mesenchymal tumors associated with rearrangements of the EWSR1 gene has been growing in recent years due to
progress in molecular detection techniques. Originally identiﬁed as the gene involved in the pathogenesis of Ewing sarcoma, the
EWSR1 gene is now known to be rearranged in diverse clinical and histopathological entities. +e NFATC2 gene is one of the
many translocation partners of EWSR1 in gene fusions in amorphologically typical, albeit rare, subgroup of mesenchymal tumors.
Little is known about the clinical characteristics of tumors containingNFATC2 gene rearrangements since most of the few reports
published describe molecular rather than clinical aspects. In the current study, we report three patients with tumors carrying the
EWSR1-NFATC2 gene translocation, including one rare primary tumor of soft tissues. Another patient with a benign-appearing
bone tumor with a unique FUS-NFATC2 gene translocation is described. In various mesenchymal tumors (e.g., myxoid/round cell
liposarcoma, low-grade ﬁbromyxoid sarcoma, or angiomatoid ﬁbrous histiocytoma), the FUS gene, as a member of the TET
family, may be alternatively rearranged instead of the EWSR1 gene without any noticeable inﬂuence on the microscopical
appearance or clinical outcome. +is fact seems not to apply to mesenchymal tumors with the involvement of the NFATC2 gene
because both in our experience and according to the extensive literature review, they have diﬀerent properties on the mor-
phological and molecular level. Both ESWSR1-NFATC2 and FUS-NFATC2 fusion-carrying tumors do not show microscopical or
clinical features of Ewing sarcoma.
1. Introduction
+e current WHO classiﬁcation [1] incorporates molecular
alterations into the subtyping of mesenchymal soft tissue
tumors, and the detection of speciﬁc genetic alteration is an
important complement in standard histopathologic di-
agnostics [2, 3]. +e EWSR1 was the ﬁrst gene identiﬁed in
relation to the pathogenesis of a mesenchymal tumor in the
early 90s [4]. Initially associated with the pathogenesis of
Ewing sarcoma (ES), this gene is now known to play a
pathogenic role in various mesenchymal and even some
epithelial tumors [5–8]. EWSR1 fusions with genes from the
ETS transcription factor family [9–11] lead to the devel-
opment of ES, a highly aggressive, undiﬀerentiated, round
cell tumor. In contrast, rearrangements of EWSR1with other
partners are found in a morphological and clinical spectrum
of entities, ranging from highly aggressive (clear cell sarcoma
(CCS) and round cell-containing myxoid liposarcoma
(RMLPS)) to less aggressive tumors (pure myxoid lip-
osarcoma (MLPS) or extraskeletal myxoid chondrosarcoma
(EMC)) [7, 8]. Some undiﬀerentiated, round cell tumors
without the classic EWSR1 fusions to genes from the ETS
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family have been designated Ewing sarcoma-like tumors
(ESLTs) [12–15]. Reproducible fusions CIC-DUX4 [16] and
BCOR-CCNB3 [17] have been identiﬁed in subsets of the
EWSR1-unrelated ESLT. Both the clinical course and
therapy response seem to diﬀer in such tumors compared to
typical ES. For example, CIC-DUX4 sarcomas are highly
aggressive and do not respond to the ES chemotherapy [18],
while BCOR-CCNB3 sarcomas follow more indolent course
[19].
Rare mesenchymal tumors carrying EWSR1-NFATC2
fusions have been assigned to ESLTs, probably due to partial
CD99 expression and/or involvement of the EWSR1 [20–
23]. However, recent studies demonstrate that not only
histological features, but also the molecular proﬁles of such
tumors diﬀer from ESs [24–26]. Little is known about the
malignant potential of mesenchymal tumors carrying
rearrangements of the NFATC2, since even if reported and
studied at the molecular level, the more detailed information
of clinical course is given only for very few patients
[12, 13, 20, 22–24, 26–30]. +e histological appearance of
EWSR1-NFATC2 fusion-associated tumors is quite re-
producible but shows microscopic heterogeneity and vari-
ability in the immunoproﬁle, not giving a pathognomonic
pattern. +ere is no strict correlation of the EWSR1-
NFATC2 fusion tumors to any of the currently morpho-
logically deﬁned entity. Examples of these tumors have been
identiﬁed among ESLTs: “myoepithelial tumors,”
myoepithelioma-like “MHFs of bone,” or aggressive
osteoblastomas (Table 1). +e EWSR1 FISH results with an
ampliﬁcation of the centromeric signal may serve as an
important diagnostic hint.
Several mesenchymal tumors (e.g., ES, MLPS, or AFH)
may contain fusions, in which FUS is alternatively rear-
ranged instead of EWSR1. In such instances, no noticeable
diﬀerences in morphology or clinical behaviour between
EWSR1- and FUS-rearranged variants are observed. Few
cases of FUS-NFATC2 fusion-associated undiﬀerentiated
ESLTs have been reported in two recent studies [26, 33] with
only limited clinicopathological information. +e molecular
proﬁles of EWSR1-NFATC2 and FUS-NFATC2 were,
however, strikingly diﬀerent [26].
In the current study, we describe three patients with
EWSR1-NFATC2 fusion-associated tumors. Initial histo-
logic diagnoses were sclerosing epithelioid ﬁbrosarcoma
(SEF), myoepithelial tumor, and EMC-like tumor. We
provide detailed histopathologic, immunohistochemical,
molecular, and clinical information as a basis for better
characterisation of this molecular category, emphasizing
their distinction from ESs and ESLTs. An additional ex-
ceptional case of a clinically indolent and microscopically
bland bone tumor mimicking aneurysmal bone cyst (ABC)
containing the FUS-NFATC2 fusion is described. EWSR1-
NFATC2- and FUS-NFATC2-associated tumors are dis-
cussed in the context of the published literature.
2. Materials and Methods
Cases with detectable rearrangements of the NFATC2 were
retrieved from the ﬁles of the Institute of Pathology,
University Hospital, Zurich, Switzerland. Two older cases
(Cases 1 and 2) showing suggestive microscopical pattern
and EWSR1 FISH ﬁndings were studied by NGS retro-
spectively, while the other two cases are current and were
studied by NGS included in the routine diagnostic work-up.
Clinical and follow-up data were obtained from clinical
databases of the involved institutions. +e study was ap-
proved by Institutional Review Board (Cantonal Ethics
Committee; KEK_ZH_2013_0430).
2.1. Histology and Immunohistochemistry. Tumor tissue
samples were ﬁxed in buﬀered 4% formalin, embedded in
paraﬃn, and stained according to standard procedures.
Immunohistochemistry (IHC) using the broad-spectrum
cytokeratin (AE1/AE3, Dako, Baar, Switzerland), CD99
(12E7, Abcam Ltd., Cambridge, UK), EMA (E29, Dako AG,
Baar, Switzerland), and MIB1 (30-9, Ventana Roche, Basel,
Switzerland) antibodies was performed, using the Ventana
Benchmark XT Automated system (Ventana Medical Sys-
tems, Tucson, Arizona).
2.2. Fluorescence In Situ Hybridization (FISH). FISH studies
were performed on formalin-ﬁxed, paraﬃn-embedded, 2 μm
thick sections. Dual-color break-apart FISH detecting
translocations involving the EWSR1 and FUS genes (both
from Vysis, Abbott AG, Baar, Switzerland) and NR4A3 gene
(ZytoVision GmbH, Bremerhaven, Germany) was per-
formed using commercially available probes. Fluorescence
staining was visualized with an Olympus BX61-microscope
(Olympus, Volketswil, Switzerland) equipped with DAPI,
SpectrumGreen, and SpectrumOrange ﬁlters. Images were
acquired with a CCD camera and processed with AnalySIS
software (Soft Imagining System, Munster, Germany). At
least 50 nonoverlapping nuclei were analysed. If the sample
contained at least 25% split red and green signals (separation
by at least twice the distance occupied by a single probe), the
tumor was regarded as rearranged.
2.3. Next Generation Sequencing (NGS). High-throughput
analysis was performed as previously described [34]. Brieﬂy,
RNA was extracted using the Maxwell 16 LEV RNA FFPE
Puriﬁcation Kit (Promega Corporation). Libraries were
prepared using Anchored-Multiplex-PCR with the com-
mercially available Archer FusionPlex Sarcoma Panel
(ArcherDx, Boulder, CO). +e RNA input was 250 ng, and
cDNA was synthesized using random primers. Libraries
were quantiﬁed using qPCR (KAPA Biosystems, South San
Francisco, CA, USA). Samples were sequenced on the MiSeq
platform (Illumina, San Diego, CA, USA). +e resulting
FASTQ ﬁles were analyzed using the standard RNA-fusion
workﬂow as implemented in the Archer Analysis Suite 5.1.3.
3. Results
+e clinical characteristics of the four patients are sum-
marized in Table 2.
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3.1. Histopathology and Immunohistochemistry
3.1.1. Case 1. Core biopsy from a large intraosseous and
extraosseous, cortex-based tumor of the diaphysis of the
right femur in a 34-year-old woman (Figure 1) showed a
partially necrotic, cellular proliferation of monomorphic,
small, blue, and round cell population, which was embedded
in a sclerotic stroma, resulting in a striking trabecular ap-
pearance. +ere was no evidence of typical osteoid or
mineralisation. +e immunophenotype was nonspeciﬁc
(CK−, S100−, Des−, and CD45−); however diﬀuse CD99
expression was found. An unusual rearrangement pattern
with an ampliﬁed and split red signal was found in the
EWSR1 FISH, which at the time of the diagnosis 11 years ago
had not been previously described and was considered
diﬃcult to interpret and unusual for ES. +e RT-PCR of the
EWSR1-FLI1 and EWSR1-ERG fusions was negative. Al-
though largely a diagnosis of exclusion, the microscopic
ﬁndings were considered consistent with sclerosing epi-
thelioid ﬁbrosarcoma (SEF). MUC4 immunostaining was
not available at the time of the diagnosis and was negative
retrospectively. No further tumormanifestations were found
on staging. +e clinical decision was made to treat the
patient with preoperative chemotherapy according to the
EURAMOS protocol [35]. Subsequent complete tumor re-
section revealed no chemotherapy-induced necrosis.
4.5 years after the initial presentation, a 1 cm skin metastasis
on the ipsilateral thigh was completely excised and showed
Table 1: Published data of patients with tumors containing EWSR1-NFATC2 fusion.
Literature
case nr Reference
Age
(y) Gender Site Original diagnosis Follow-up/outcome +erapy
1
[22, 31]
39 M HumerusR ESLT
15mo after surgery
lung met
Resection post-op Chth
EuroEwing 99
26mo after surgery
bone met spine
40mo after surgery
2nd lung met
48mo after surgery
ANED
2 16 M Femur R ESLT ND ND
3 21 M +igh R ESLT ND ND
4 25 M Femur R ESLT ND ND
5 [29] 32 M Lowerlimb
Myoepithelial-like
“MFH”
of bone 7 y before
radiation due to
lymphoma
64mo; ANED (never
metastasized) ND
6
[28]
12 M Femur ES 11mo; ANED (nevermetastasized) Pre-op Chth resection
7 28 M Humerus Lymphoma 4 y local recurrence 4 y lungmetastasis “possible” Chth (“standard protocol”)
8 [12] 42 M Femur R ND ND
9 [30] 30 M Femur L
Aggressive osteoblastoma
osteosarcoma
(recurrence)
2.5 y post-op local rec 3.5 y
ANED
Curettage and bone graft
2.5 y post-op Chth after
local recurrence
10 [27] 24 F Calfsubcutis Extraskeletal ES
12mo; ANED (never
recurrence or metastases) Pre-op Chth Ewing protocol
11 [32] ND ND Fibula ESLT ANED (how long?) ND
12
[26]
32.7 M Humerus ES ND ND
13 12.7 F Tibia ES ND ND
14 61.5 M Calf ES ND ND
15 23.6 M Femur ES ND ND
16
Current
study
34 F Femur R SEF 4.5 y skin metastasis 10.5 ylung metastasis 11 y ANED
Pre-op Chth EURAMOS
protocol resection
17 42 M Tibia L Myoepithelal tumor 8.5 y ANED
Curettage resection
amputation (due to surgical
complications)
18 60 F Abdomen Myoepithelal tumor orEMC 8mo ANED Resection
19–24 [20] ND ND ND ES/ESLT ND ND
25 [23] ND ND ND ES/ESLT ND ND
26–32 [24] ND ND ND ES/ESLT ND ND
ANED: alive, no evidence of disease; Chth: chemotherapy; EMC: extraskeletal myxoid chondrosarcoma; ES: Ewing sarcoma; ESLT: Ewing sarcoma-like
tumor; F: female; L: left; ND: no data; M: male; mo: months; R: right; SEF: sclerosing epithelioid ﬁbrosarcoma; y: years.
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identical microscopical pattern as the primary. +e patient
was regularly followed, and 10.5 years after the ﬁrst pre-
sentation, a solitary 7mm lung metastasis was resected.
Currently (11 years follow-up), the patient is doing well
without known tumor manifestation. NGS analyses per-
formed retrospectively on the skin metastasis revealed the
EWSR1-NFATC2 gene fusion.
3.1.2. Case 2. Due to diﬃcult histologic interpretation and
extensive necrosis, two core biopsies were performed at
external institutions, followed by the curettage of an
intraosseous and extraosseous process of a 42-year-old man
with clinical suspicion of an osteomyelitis of the left tibia
(Figure 2). +e tumor cells were small and inconspicuous,
grouped in solid nests and trabecula, embedded in collagen-
rich matrix. +e cytoplasm was clear with distinct borders.
+ere were few mitoses and a low proliferation index. +e
immunophenotype revealed diﬀuse, weak expression of
cytokeratin, focal CD99 positivity, and coexpression of
EMA, CD10, and CD117. Immunolabeling for S100, SMA,
desmin, p63, CD34, and CD45 was negative. Nuclear ex-
pression of INI1 was retained. EWSR1 FISH showed a
rearrangement pattern of an ampliﬁed split red signal. RT-
PCRs of the EWSR1-FLI1 and EWSR1-ERG fusions were
negative. Based on the microscopic appearance, cytokeratin
expression and low proliferation rate, the diagnosis of a
primary low-grade myoepithelial carcinoma was rendered.
No further tumor manifestations were found upon staging.
Local complete resection with reconstruction was per-
formed. Persistent surgical complications led to amputation
7 years later. No adjuvant therapy was given. Neither local
nor systemic tumor manifestations were found with a
follow-up of altogether 8.5 years. Retrospective NGS of the
curettage sample revealed the EWSR1-NFATC2 fusion.
3.1.3. Case 3. Core biopsy of an intra-abdominal epigastric
mass in a 60-year-old woman (Figure 3) showed mesen-
chymal tumor with abundant extracellular matrix, com-
posed of a trabecular network of monomorphic cells.
Immunohistochemistry was negative for GIST markers as
well as S100, HMB45, SMA, desmin, synaptophysin, STAT6,
and MUC4. +e nuclear expression of INI1 was retained.
Rare cells expressed cytokeratin and EMA. Diﬀuse weak
CD99 expression was observed. +e diﬀerential diagnosis
included EMC and myoepithelial tumor. As both categories
may show rearrangement of the EWSR1, FISH was per-
formed revealing rearrangement with low-level ampliﬁca-
tion of the red signal.NR4A3 FISH showed a normal pattern,
excluding the diagnosis of EMC. NGS analysis of the re-
section specimen revealed the EWSR1-NFATC2 fusion. No
adjuvant therapy was given, and no further tumor mani-
festations were found upon staging.
3.1.4. Case 4. Core biopsy of a metaphyseal mass of the right
humerus in a 12-year-old boy (Figure 4) revealed an
intramedullar bland spindle-cell proliferation with focal
siderin depositions and few osteoclast-type giant cells. No
necrosis or mitotic activity was observed. +ere was no
osteoid or cartilage production. Given the radiologic dif-
ferential diagnosis of an aneurysmal bone cyst (ABC), USP6
FISH was performed which was inconclusive. NGS, initially
performed on the core biopsy and repeated independently
on the subsequent curettage, revealed the same FUS-
NFATC2 fusion in both specimens. FUS FISH performed for
veriﬁcation of the NGS showed the classical break-apart
pattern without ampliﬁcation. +e lesional tissue showed
very low proliferative activity in the MIB1 staining (<5%).
Diﬀuse expression of EMA and CD99 was seen, while the
reaction for SMA, desmin, S100, CD34, and synaptophysin
remained negative.+e curettage did not contain high-grade
tumor. At 8months follow-up, there was no evidence of
recurrent tumor on the control MRI.
3.2. Fluorescence In Situ Hybridization (FISH)/Next Gener-
ation Sequencing (NGS). In cases 1, 2, and 3, the break-apart
probe for the EWSR1 gene (Figures 1(j), 2(j), and 3(f ))
showed an unusual pattern for break-apart probes with one
to three fused signals and several grouped and ampliﬁed red
signals. +is pattern diagnostic of gene rearrangement,
however, indicates that the break within chromosome 22q is
associated with additional aberrations. Since a diﬀerential
diagnosis of EMC was considered in case 3, a second NR4A3
FISH reaction was performed and was negative (Figure 3(e)).
In all three cases 1, 2, and 3, an EWSR1-NFATC2 fusion was
found on NGS.
Table 2: Clinical data of the study patients.
No. Gender Age(y) Site Primary Dg +erapy Follow-up Outcome
1 F 34 Femur R SEF Neoadj. Ch+; resection 4.5 y skin met (thigh R); 8.5 y-lung met (OL R)
11 y;
NED
2 M 42 Tibia L Myoepithelialtumor
Curretage, resection 1 y later;
amputation 7.5 y post-op due to
surgical complications
8.5 y;
NED
3 F 60 Upperabdomen
Myoepithelial
tumor or EMC Resection
8mo;
NED
4 M 12 HumerusR
Compatible with
ABC Intralesional curettage
8mo;
NED
ABC: aneurysmal bone cyst; Ch+: chemotherapy; EMC: extraskeletal myxoid chondrosarcoma; L: left; NED: no evidence of disease; R: right; SEF: sclerosing
epithelioid ﬁbrosarcoma; y: years.
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(a) (c)
(g)(f)(e)
(h) (i) (j)
(d)
(b)
Figure 1: Tumor of the diaphysis of the right femur in a 34-year-old woman. Imaging studies ((a) conventional radiogram, (b) CT, (c) MRI,
and (d) PET/CT) revealed a cortex-based mass with intraosseous and extraosseous extension, corresponding to the multilobulated tumor in
the cut section of the resection specimen (g). (e) Direct smear of the biopsy (Papanikolaou stain, 400x) showed small, blue, round cell
population. (f ) On histologic examination, the tumor displayed a prominent collagen-rich extracellular matrix (H&E; 200x) with amoderate
proliferation rate ((h) MIB1 immunohistochemistry; 100x) and strong CD99 expression ((i) 400). (j) Break-apart probe FISH analysis of the
EWSR1 gene showed one to two fused signals (white arrows) and low-grade ampliﬁed red signals (red arrows) in the tumor cell nuclei,
suggesting the rearrangement of the EWSR1 gene with additional chromosomal aberrations.
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+e diﬀerential diagnosis in case 4 of the osteolytic
(Figures 4(a) and 4(b)), giant cell containing histologically
bland proliferation (Figures 4(c)–4(f)) in the metaphysis of a
young patient included anABC.USP6 FISHwas inconclusive,
suggesting the lack of the rearrangement. A FUS-NFATC2
gene fusion was detected on NGS performed independently
(a) (c)
(g)(f)(e)
(h) (i) (j)
(d)
(b)
Figure 2: Imaging of a painful lesion of the proximal diaphysis of the left tibia in a 42-year-oldman ((a, b) CT, (c) 3DCTreconstruction, and
(d) MRI) showed a cortex-based mass with intraosseous and extraosseous extension. (e) Direct smear of the biopsy (Papanikolaou stain,
400x) showed a small, blue, round cell population. (f ) Histological examination revealed tumor cells with clear cytoplasm, embedded in
collagen-rich extracellular matrix (H&E; 200x). +e cells have a low proliferation rate ((g) MIB1 immunohistochemistry; 100x) and focal
cytokeratin (AE1/AE3) ((h) 200x) and CD99 expression ((i) 400). (j) On break-apart probe FISH analysis of the EWSR1 gene, one to two
fused signals (white arrows) and low-grade ampliﬁed red signals (red arrows) in the tumor cell nuclei were seen, suggesting rearrangement
of the EWSR1 gene with additional chromosomal aberrations.
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and metachronically, both on the core biopsy as well as the
curettage specimen. +is result was veriﬁed with FUS FISH,
which showed classical break-apart pattern with one fused
and one split signal in both samples (Figure 4(e)).
3.3. Follow-Up. All four patients are currently alive and
without tumor manifestations. Patient 1 developed skin
metastasis involving the thigh, four and a half years
following the ﬁrst diagnosis and a small lung metastasis six
years later. Both lesions were completely resected without
additional therapy. Patient 2 suﬀered several local surgical
complications, which resulted in amputation of the lower leg
at 7.5 years after the initial diagnosis. At 8.5 years after the
diagnosis, the patient is free of tumor at 8.5 years without
adjuvant therapy. +e 8-month follow-up for patients 3 and
4 is still rather short to draw ﬁnal conclusions; however, both
patients are free of tumor.
(d)
(f)
(c)
(e)
(a) (b)
Figure 3: CT imaging in a 60-year-old woman showed an isolated upper intraabdominal mass ((a) red asterisk). (b) Moderately cellular
tumor with a prominent chondromyxoid matrix and trabecular growth pattern (H&E stain; original magniﬁcation 200x). (c) Rare mitoses
are present (arrows) (H&E; 400x). (d) Heterogeneous proliferation index of up to 30% (MIB1 immunohistochemistry; 200x). (e) No
rearrangement of the NR4A3 gene in FISH analysis, excluding extraskeletal myxoid chondrosarcoma (arrows: exclusively fused signals). (f )
Break-apart FISH analysis of the EWSR1 gene demonstrated an unusual pattern of one to three fused signals (white arrows) and low-grade
ampliﬁed red signals (red arrows) in tumor cell nuclei, suggesting rearrangement of the EWSR1 gene with additional chromosomal
aberrations.
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4. Review of the Published Literature
4.1. EWSR1-NFATC2. Review of the published literature in
the PubMed databank revealed 8 papers with at least
minimal clinical information on 15 patients with tumors
carrying the EWSR1-NFATC2 fusion [12, 13, 22, 26–30]
(Table 1). Fourteen more cases lacking clinical information
are mentioned in three further studies with a special focus on
(a)
(c)
(b)
(f) (g) (h)
(d) (e)
Figure 4: Symptomatic bone lesion in the metaphysis of the right proximal humerus of a 12-year-old boy. (a) CT and (b) MRI imaging
demonstrated an irregular, partially osteolytic lesion. (c) Core biopsy revealed giant cells (arrows) containing bland spindle cell proliferation.
(d) Curettage showed similar lesional tissue without necrosis, pleomorphism, or mitotic activity; however, a conspicuous biphasic pattern
was observed (d, f ).+e distinctive spindle cell population contained siderin and mast cells and expressed immunohistochemically EMA (g)
and CD99 (not shown), while the adjacent EMA and CD99 negative areas showed SMA expression (h). (e) FISH analysis with a break-apart
probe demonstrated one fused (arrowhead) and one split (arrows) signal, indicating the rearrangement of the FUS gene.
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the molecular proﬁling of ES and ESLT [20, 23, 24]. Of the
cases with clinical information, there was a striking male
predominance with 14 males and 4 females. Of the 17 pa-
tients with adequate data, only three where younger than 18;
the youngest patient reported was 12-year-old and the oldest
61.5-year-old (median 30, mean age 31.5 years). Only three
cases were described in soft tissue (two in the calf and one
intra-abdominal), while the rest occurred in long bones (8
femur, 3 humerus, 2 tibia, 1 ﬁbula; one tumor “lower limb”).
Follow-up data are available for 9 patients (including 3
patients of the current study) with all reported as alive, with
follow-up ranging from 8months to 11 years (mean
52months). In case of the tenth patient, who is reportedly
alive and tumor-free, no follow-up period is speciﬁed.
Metastases have been detected in only two patients (one with
lung and bone metastases and the other with skin and lung
metastases) and local recurrence in 3 patients. +e data on
treatment are even more scarce: six patients underwent
chemotherapy (including ES protocol in 4 patients, one for
falsely diagnosed lymphoma, and one EURAMOS) and were
treated by surgery.
4.2. FUS-NFATC2. Two publications describe 4 patients
harbouring tumors the FUS-NFATC2 fusion detected in the
context of molecular proﬁling of ES/ESLT [26, 33] (Table 3).
Gender and age (three male patients: 15-, 22-, and 43-year-
olds and a 49-year-old woman) as well as tumor locations
(all in femur) are given; however, no details on therapy or
especially follow-up or outcome are provided. Histologi-
cally, they are described as mitotically active with necrosis
and areas comprising both round cell and spindle cell
features, accompanied by focal chondroid diﬀerentiation or
myxohyaline stroma [26, 33]. Molecular proﬁling with
clustering analyses [26] suggests that there is a substantial
diﬀerence between the FUS-NFATC2 and EWSR1-NFATC2
tumors since they show distinct and unrelated signatures.
+e patient described in the current study is the youngest
reported with a tumor harbouring FUS-NFATC2 fusion. In
addition, this tumor represents the ﬁrst case with a FUS-
NFATC2 fusion without microscopic or clinical evidence of
high-grade malignancy.
5. Discussion
Following the recognition that Ewing sarcoma is patho-
genically caused by translocations of a gene located on
chromosome 22q12 (subsequently called Ewing sarcoma
gene) to partner genes of the ETS family of transforming
factors, a subgroup of mostly aggressive sarcomas not
carrying this translocation type has been identiﬁed and
designed as “Ewing sarcoma-like tumors” (ESLT) [12–15].
+e term ESLT has subsequently been applied to some
unclassiﬁable tumors, which did not ﬁt in any category of
established entities and while only remotely resembling ES,
showed variable immunohistochemical expression of CD99
antigen and/or the involvement of EWSR1, not linked to a
partner from the ETS family. EWSR1 rearrangements are
involved in the pathogenesis of several well-established
clinically and morphologically obviously non-ES, non-
ESLT, entities such as MLPS, CCS, AFH, and a subgroup
of myoepithelial tumors of soft tissue [7, 8].
In the current study, we describe three patients with
tumors characterised by the EWSR1-NFATC2 fusion.
NFATC2 (nuclear factor of activated T-cells, calcineurin-
dependent 2) gene is involved in the function of the activated
T-cell transcription complex [21]. Several studies (Table 1)
describe tumors carrying EWSR1-NFATC2 fusion, mostly
identiﬁed among tumors at ﬁrst classiﬁed as ESLTs. +e
comparison of the histopathology of these tumors suggests
that they show a quite typical microscopic appearance with
trabecular growth pattern and sclerotic, myxohyaline ma-
trix, which substantially diﬀers from the round cell aspect of
typically stroma-devoid ESs and in fact resembles rather
neoplasias from the spectrum of myoepithelial tumors.
Rearrangements of EWSR1 with various partners [36–40]
have been described in a subgroup of soft tissue myoepi-
thelial tumors. Other subgroups of myoepithelial tumors of
soft tissue are associated with alternative genetic aberrations
such as rearrangements of other genes (e.g., PLAG1 [41]) or
homozygous deletion of the INI1/SMARCB1 gene [42–44],
while in a large proportion, the genetic background is not yet
known. In fact, one of the tumors of the current series was
initially diagnosed as a myoepithelial carcinoma due to the
expression of cytokeratins and the presence of the EWSR1
rearrangement. +e intra-abdominal tumor of patient 3 was
initially considered to be either a myoepithelial tumor or an
EMC based on the rearrangement of the EWSR1. Another
tumor reported in the literature was identiﬁed as
myoepithelioma-like sarcoma of bone [29] in retrospective
work-up of 57 undiﬀerentiated bone sarcomas.
+e ﬁrst case of our series with currently the longest
reported follow-up in the literature was diagnosed 11 years
ago as a sclerosing epithelioid ﬁbrosarcoma (SEF), which
already then was considered to be an exclusion diagnosis. At
the time of the initial diagnosis, the concept of primary
myoepithelial tumors of soft tissue and bones was not yet
well established and little was known on the molecular
background of SEF and the MUC4 immunohistochemis-
try—nowadays easy to apply to verify this diagnosis—was
not yet available.
+e molecular hallmark of the EWSR1-NFATC2 fusion
is the accompanying secondary structural aberration of the
fusion product, which leads to low-level ampliﬁcation of the
centromeric portion of the probe on the break-apart FISH.
+is pattern is very typical and was observed in all cases
reported so far. In fact, this ﬁnding should serve as a ﬁrst
diagnostic hint of the EWSR1-NFATC2-translocated
sarcomas.
Tumors carrying the EWSR1-NFATC2 fusion have been
reported mostly in long bones of male patients with only few
reports in soft tissue or in female patients. +e intra-
abdominal tumor of the female patient 3 of our series is
to the best of our knowledge the ﬁrst reported in a non-
extremity location. Patients with EWSR1-NFATC2 tumors
are generally older than ES patients, with the median age of
30 years at presentation for the cases with reported age data,
even if these tumors do occur below the age of 20. Apart
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from local destructive growth, a fraction of reported patients
developed lung and rare skin or bone metastases, conﬁrming
the malignant potential of EWSR1-NFATC2 fusion-
associated tumors. However, long survival periods, even
without adjuvant therapy and the lack of reported deaths due
to tumor, indicate that these tumors belong to the low-grade
malignant category. +e relation of EWSR1-NFATC2-
translocated tumors to the group of ESs and ESLTs is
currently being controversially discussed in the literature
[27, 45, 46]. Based on our experience and the review of the
data from the published literature, these tumors merit
consideration of a separate category.
+e FUS gene as a member of the TET/FET family has
been found to be alternatively rearranged instead of EWSR1
in several mesenchymal entities such as ES, MLPS, LGFMS,
or AFH, without noticeable diﬀerences in morphology or
clinical course. +e FUS similar to EWSR1 codes for a TET
family member of RNA-binding proteins sharing homolo-
gous sentences. +e 5′ transactivation domain of FUS and
EWSR1 seems to be interchangeable in terms of trans-
forming potential, and the fusion proteins resulting from
EWSR1 or FUS rearrangements with any given partner seem
to exert identical biological eﬀects [14]. Interestingly,
however, in cases of FUS gene-related ES, the fusion partners
involve the ETS genes ERG or FEV, but not FLI1, which is
the most commonly rearranged partner of EWSR1 in ES. In
two recent studies, isolated cases of FUS-NFATC2 fusion
associated tumors have been cited in the literature among
undiﬀerentiated ESLTs (Table 3) [26, 33] with only limited
information on the histopathology and clinical features. Of
note, the molecular proﬁles of EWSR1-NFATC2 and FUS-
NFATC2 tumors were strikingly diﬀerent. +is observation
suggests that contrary to previously described tumors with
EWSR1 and/or FUS genes fused to other genes than
NFATC2, substantial diﬀerences must exist. +e FISH
pattern of the FUS rearrangement is not described in the two
papers reporting the FUS-NFATC2-associated tumors. In
case 4 of the current series, in contrast to the EWSR1-
NFATC2 fusion, the FUS-NFATC2 fusion was not associated
with ampliﬁcation of the aﬀected FUS region on FISH,
implying a diﬀerent structure of the fusion product. +e
histological features of case 4, which lack morphological and
clinical evidence of malignancy, appear to diﬀer from the
three cases of ESLTdescribed in the literature. More data are
required regarding the clinical, histopathological, and mo-
lecular properties of tumors carrying the FUS-NFATC2
fusion.
+e current study and literature review underscore the
observation that the EWSR1-NFATC2 fusion-associated
tumors are distinct histopathological and molecular enti-
ties that probably should not be included in the ESLT cat-
egory. Only a handful of reported cases with incomplete
clinical data are available on FUS-NFATC2 fusion-associated
neoplasia. However, interestingly, based on case 4 of the
current study and previous molecular proﬁling data [26],
there seems to be a diﬀerence between tumors having either
the ESWR1 or FUS as the fusion partner ofNFATC2 gene. As
we move towards a molecular classiﬁcation of mesenchymal
tumors, much remains to be learned about the correlation of
the speciﬁc genetic aberrations with the clinical outcome and
the response to therapy.
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